Antigen-based vaccination and prevention of type 1 diabetes

Current Diabetes Reports

Volumn 13, Issue 5, 2013, Pages 616-623

  Harrison, Leonard C ^a   Wentworth, John M ^a   Zhang, Yuxia ^a   Bandala Sanchez, Esther ^a   Böhmer, Ralph M ^a   Neale, Alana M ^a   Stone, Natalie L ^a   Naselli, Gaetano ^a   Bosco, Julian J ^a   Auyeung, Priscilla ^a   Rashidi, Maryam ^a   Augstein, Petra ^a   Morahan, Grant ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

cell; Antigen; Autoantibody; Autoimmune; Clinical trial; GAD65; Immune; Insulin; Islet; Mucosa; Nasal; Oral; Preclinical; Prediction; Prevention; Regulation; Suppression; T cell; Tolerance; Type 1 diabetes; Vaccination

Indexed keywords

AUTOANTIGEN; C PEPTIDE; GLIPIZIDE; GLUTAMATE DECARBOXYLASE 65; HEMOGLOBIN A1C; INSULIN; TRANSCRIPTION FACTOR FOXP3;

ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; GENE LOCUS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL; RISK FACTOR; T LYMPHOCYTE; VACCINATION;

ANIMALS; AUTOANTIGENS; DIABETES MELLITUS, TYPE 1; GLUTAMATE DECARBOXYLASE; HUMANS; INSULIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VACCINATION;

EID: 84884592691     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-013-0415-7     Document Type: Article

References (61)

1. Harrison LC. Vaccination against self to prevent autoimmune disease: the type 1 diabetes model. Immunol Cell Biol. 2008;89:139-45.
2. Faria AM, Weiner HL. Oral tolerance: mechanisms and therapeutic applications. Adv Immunol. 1999;73:153-64.
3. Harrison LC, Hafler DA. Antigen-specific therapy for autoimmune disease. Curr Opin Immunol. 2000;12:704-11.
4. Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol. 2010;11:7-13.
5. Bennett CL, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001;27:20-1.
6. Zhang Y, Bandala-Sanchez E, Harrison LC. Revisiting regulatory T cells in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2012;19:271-8.
7. Curotto de Lafaille MA, Lafaille JJ. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity. 2009;30:626-35.
8. Narendran P, Mannering SI, Harrison LC. Proinsulin - a pathogenic autoantigen in type 1 diabetes. Autoimmun Rev. 2003;2:204-10.
9. Zhang L, Nakayama M, Eisenbarth GS. Insulin as an autoantigen in NOD/human diabetes. Curr Opin Immunol. 2008;20:111-8.
10. Krishnamurthy B, Dudek NL, McKenzie MD, et al. Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP. J Clin Invest. 2006;116:3258-65.
11. Harrison LC. Risk assessment, prediction and prevention of type 1 diabetes. Pediatric Diabetes. 2001;2:71-82.
12. Fourlanos S, Narendran P, Byrnes G, Colman P, Harrison LC. Insulin resistance is a risk factor for progression to type 1 diabetes. Diabetologia. 2004;47:1661-7.
13. Shah SC, Malone JI, Simpson NE. A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus. N Engl J Med. 1989;320:550-4.
14. Selam JL, Woertz L, Lozano J, et al. The use of glipizide combined with intensive insulin treatment for the induction of remissions in new onset adult type I diabetes. Autoimmunity. 1993;16:281-8.
15. Linn T, Ortac K, Laube H, Federlin K. Intensive therapy in adult insulin-dependent diabetes mellitus is associated with improved insulin sensitivity and reserve: a randomized, controlled, prospective study over 5 years in newly diagnosed patients. Metabolism. 1996;45:1508-13.
16. Kobayashi T, Nakanishi K, Murase T, Kosaka K. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive b-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes. 1996;45:622-6.
17. Schnell O, Eisfelder B, Standl E, Ziegler AG. High-dose intravenous insulin infusion versus intensive insulin treatment in newly diagnosed IDDM. Diabetes. 1997;46:1607-11.
18. Füchtenbusch M, Rabl W, Grassl B, et al. Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial. Diabetologia. 1998;41:536-41.
19. Pozzilli P, Pitocco D, Visalli N, et al. No effect of oral insulin on residual beta-cell function in recent-onset type 1 diabetes (the IMDIAB VII). IMDIAB Group. Diabetologia. 2000;43:1000-4.
20. Chaillous L, Lefevre H, Thivolet C, et al. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabete Insuline Orale group. Lancet. 2000;356:545-9.
21. Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med. 2002;346:1685-91.
22. Harrison LC, Honeyman MC, Steele CE, et al. Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care. 2004;27:2348-55.
23. Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care. 2005;28:1068-76.
24. Nanto-Salonen K, Kupila A, Simell S, et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet. 2008;372:1746-55.
25. Walter M, Philotheou A, Bonnici F, Ziegler AG, Jimenez R. NBI-6024 Study Group: no effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes. Diabetes Care. 2009;2:2036-40.
26. Orban T, Farkas K, Jalahej H. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun. 2010;34:408-15.
27. •• Fourlanos S, Perry C, Gellert SA, et al. Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes. Diabetes. 2011;60:1237-45. In a randomized controlled trial, nasal insulin markedly suppressed the antibody response to a subsequent "challenge" by subcutaneous insulin. This is the first evidence of immune tolerance to a mucosally administered autoantigen and provides a rationale for trials of mucosal insulin vaccination in people at risk for T1D.
28. Agardh CD, Cilio CM, Lethagen A, et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications. 2005;19:238-46.
29. Ludvigsson J, Faresjo M, Hjorth M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med. 2008;359:1909-20.
30. •• Ludvigsson J, Krisky D, Casas R, et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med. 2012;366:433-42. This large randomized trial of subcutaneous GAD65 with alum as adjuvant followed an earlier trial by the same investigators [ref. 29] that suggested that the vaccine reduced the decline in β-cell function after diagnosis. In the previous trial, 70 patients 10-18 years of age with T1D for less than 18 months were treated with two 20-μg doses of either GAD-alum or placebo a month apart. Changes in fasting and meal-stimulated C-peptide secretion were similar after 15 months but declined less in those treated with GAD-alum within 6 months of diagnosis. Here, 334 patients of similar age but diagnosed less than 3 months were randomized to two doses of GAD-alum or placebo. GAD65-alum induced antibodies to GAD65 and was not associated with major side effects, as previously, but did not alter the decline in β-cell function.
31. •• Wherrett DK, Bundy B, Becker DJ, et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet. 2011;378:319-27. This well-powered randomized controlled trial in 145 people with recent-onset T1D (<3 months) showed that subcutaneous GAD65-alum did not arrest the decline in age-adjusted meal-stimulated C-peptide secretion after 1 year. This finding conclusively demonstrates that the GAD-alum vaccine is ineffective in people with clinical T1D but does not exclude possible efficacy in people with subclinical disease or those genetically at risk.
32. • Mamchak AA, Manenkova Y, Leconet W, et al. Preexisting autoantibodies predict efficacy of oral insulin to cure autoimmune diabetes in combination with anti-CD3. Diabetes. 2012;61:1490-9. The authors demonstrate synergy between treatment with anti-CD3 monoclonal antibody and oral insulin in reversing hyperglycemia at diagnosis in NOD mice. This is a rationale for combining autoantigen-specific vaccination with conventional immune suppression. In addition, they show that a high serum concentration of insulin autoantibody (IAA) predicts response to combination treatment. This echoes the post-DPT-1 oral insulin trial finding [ref. 23] that slower progression to diabetes after oral insulin was associated with higher IAA at entry. How insulin autoimmunity relates to a tolerogenic response to insulin requires an answer; meanwhile, IAA could be a useful biomarker.
33. Weiner HL, Mackin GA, Matsui M. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science. 1993;259:1321-4.
34. Trentham DA, Dynesius-Trentham RA, Orav EJ. Effects of oral administration of type II collagen on rheumatoid arthritis. Science. 1993;261:1727-30.
35. McKown KM, Carbone LD, Kaplan SB, et al. Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis. Arthritis Rheum. 1999;42:1204-8.
36. Metzler B, Wraith DC. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. Int Immunol. 1993;5:1159-65.
37. Hänninen A, Braakhuis A, Heath WR, Harrison LC. Mucosal antigen primes diabetogenic cytotoxic T-lymphocytes regardless of dose or delivery route. Diabetes. 2001;50:771-5.
38. Hänninen A, Martinez NR, Davey GM, Heath WR, Harrison LC. Transient blockade of CD40 ligand dissociates pathogenic from protective mucosal immunity. J Clin Invest. 2002;109:261-7.
39. Martinez NR, Augstein P, Moustakas AK, et al. Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide. J Clin Invest. 2003;111:1365-71.
40. Zhang ZH, Davidson L, Eisenbarth G, Weiner HL. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci U S A. 1991;88:10252-6.
41. Bergerot I, Fabien N, Maguer V, Thivolet C. Oral administration of human insulin to NOD mice generates CD4+ T cells that suppress adoptive transfer of diabetes. J Autoimmun. 1994;7:655-63.
42. Harrison LC, Dempsey-Collier M, Kramer DR, Takahashi K. Aerosol insulin induces regulatory CD8 gamma delta T cells that prevent murine insulin-dependent diabetes. J Exp Med. 1996;184:2167-74.
43. Waldo FB, Vandenwallbake AWL, Mestecky J, Husby S. Suppression of the immune response by nasal immunization. Clin Immunol Immunopathol. 1994;72:30-4.
44. Achenbach P, Barker J, Bonifacio E. Pre-POINT Study Group: Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization. Curr Diab Rep. 2008;87-93.
45. Fourlanos S, Dotta F, Greenbaum CK, et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia. 2005;48:2206-12.
46. De Aizpurua HJ, French MB, Chosich N, Harrison LC. Natural history of humoral immunity to glutamic acid decarboxylase in non-obese diabetic (NOD) mice. J Autoimmun. 1994;7:643-53.
47. Tisch R, Yang XD, Singer SM, et al. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature. 1993;366:72-5.
48. Kaufman DL, Clare-Salzler M, Tian J, et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature. 1993;366:69-72.
49. French MB, Allison J, Cram DS, et al. Transgenic expression of mouse proinsulin II prevents diabetes in non-obese diabetic mice. Diabetes. 1997;46:34-9.
50. Jaeckel E, Klein L, Martin-Orozco N, von Boehmer H. Normal incidence of diabetes in NOD mice tolerant to glutamic acid decarboxylase. J Exp Med. 2003;197:1635-44.
51. Petersen JS, Karlsen AE, Markholst H, et al. Neonatal tolerization with glutamic acid decarboxylase but not with bovine serum albumin delays the onset of diabetes in NOD mice. Diabetes. 1994;43:1478-84.
52. Tisch R, Wang B, Weaver DJ, et al. Antigen-specific mediated suppression of beta cell autoimmunity by plasmid DNA vaccination. J Immunol. 2001;16:2122-32.
53. Tian J, Atkinson MA, Clare-Salzler M, et al. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med. 1996;183:1561-7.
54. Ludvigsson J. Therapy with GAD in diabetes. Diabetes Metab Res Rev. 2009;25:307-15.
55. • Hjorth M, Axelsson S, Ryden A, et al. GAD-alum treatment induces GAD65-specific CD4 + CD25 high FOXP3+ cells in type 1 diabetic patients. Clin Immunol. 2011;138:117-26. Despite the failure of subcutaneous GAD-alum vaccine to slow the decline of β-cell function after the diagnosis of T1D [refs. 30••, 31••], this and the following study [ref. 56•] demonstrate that the vaccine has a bio-effect possibly consistent with induction of immune tolerance. It will be important to confirm and, if possible, extend these findings, because evidence for tolerance would support application of the GAD-alum vaccine for T1D prevention in at-risk individuals.
56. • Axelsson S, Hjorth M, Ludvigsson J, Casas R. Decreased GAD (65)-specific Th1/Tc1 phenotype in children with Type 1 diabetes treated with GAD-alum. Diabet Med. 2012;29:1272-8. See comments under ref. [55•] above.
57. Fourlanos S, Varney M, Tait BD, et al. The rising incidence of type 1 diabetes is accounted for by cases with lower risk HLA genotypes. Diabetes Care. 2008;31:1546-9.
58. Morahan G, Mehta M, James I, et al. Tests for genetic interactions in type 1 diabetes: linkage and stratification analyses of 4,422 affected sib-pairs. Diabetes. 2011;60:1030-40.
59. Bennett ST, Lucassen AM, Gough SC, et al. Susceptibility to human type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus. Nat Genet. 1995;9:284-92.
60. Pugliese A, Zeller M, Fernandez Jr A, et al. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet. 1997;15:293-7.
61. Narendran P, Neale AM, Lee BH, et al. Proinsulin is encoded by an RNA splice variant in human blood myeloid cells. Proc Natl Acad Sci. 2006;103:16430-5.